US2023371555A1PendingUtilityA1

Deuterated caffeine and uses thereof

Assignee: LENNHAM PHARMACEUTICALS INCPriority: Jun 14, 2019Filed: Apr 21, 2023Published: Nov 23, 2023
Est. expiryJun 14, 2039(~12.9 yrs left)· nominal 20-yr term from priority
A61K 2800/524A61K 2800/51A61K 2800/91A61Q 19/06A61K 8/34A61K 8/368A61K 8/63A61K 8/4953A23L 2/56A23L 27/31A23L 27/2054A23L 27/21A23L 27/88A23L 33/15A23L 33/175A23L 2/60A23V 2250/2108A23V 2002/00A23V 2200/33A23V 2250/154A23V 2250/0644A23V 2250/7052A23V 2250/706A23V 2250/7056A23V 2250/7046A23V 2250/161A23V 2250/705A23V 2250/0652A23V 2250/0638A23V 2250/708A23L 2/52A23L 33/10A23L 33/105A61Q 19/00
85
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, diet supplements) comprising deuterated caffeine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.

Claims

exact text as granted — not AI-modified
1 - 2 . (canceled) 
     
     
         3 . A cosmetic composition comprising a compound of Formula (I): 
       
         
           
           
               
               
           
         
         or an acceptable salt thereof;
 wherein each Y is independently hydrogen or deuterium; and 
 at least one Y is deuterium. 
 
       
     
     
         4 . (canceled) 
     
     
         5 . The composition of  claim 3 , wherein the composition is suitable for administration by injection, absorption, or implantation. 
     
     
         6 . The composition of  claim 3 , wherein the composition is suitable for topical administration. 
     
     
         7 - 14 . (canceled) 
     
     
         15 . The composition of  claim 3 , wherein at least three instances of Y are deuterium. 
     
     
         16 - 20 . (canceled) 
     
     
         21 . The composition of  claim 3 , wherein nine instances of Y are deuterium. 
     
     
         22 . The composition of  claim 3 , wherein each Y is deuterium. 
     
     
         23 - 30 . (canceled) 
     
     
         31 . The composition of  claim 3 , wherein the compound is selected from the group consisting of: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         or a pharmaceutically or nutraceutically acceptable salt thereof. 
       
     
     
         32 . The composition of  claim 3 , wherein the compound is 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically or nutraceutically acceptable salt thereof. 
     
     
         33 . The composition of  claim 3 , wherein the compound is 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically or nutraceutically acceptable salt thereof. 
     
     
         34 . The composition of  claim 3 , wherein the compound is selected from the group consisting of: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         35 . The composition of  claim 3 , wherein the compound is 
       
         
           
           
               
               
           
         
       
     
     
         36 . The composition of  claim 3 , further comprising a pharmaceutically or nutraceutically acceptable carrier. 
     
     
         37 . (canceled) 
     
     
         38 . The composition of  claim 6 , wherein the topical composition is a shampoo, conditioner, cream, foam, gel, lotion, ointment, transdermal patch, tincture, or paste. 
     
     
         39 . (canceled) 
     
     
         40 . The composition of  claim 3 , further comprising an additional agent. 
     
     
         41 - 49 . (canceled) 
     
     
         50 . The composition of  claim 3 , wherein the composition comprises about 1 mg to about 10,000 mg of the compound of Formula (I), or a salt thereof. 
     
     
         51 . The composition of  claim 50 , wherein the composition comprises about 1 mg to about 1,000 mg of the compound of Formula (I), or a pharmaceutically or nutraceutically acceptable salt thereof. 
     
     
         52 . The composition of  claim 50 , wherein the composition comprises about 1 mg to about 100 mg of the compound of Formula (I), or a pharmaceutically or nutraceutically acceptable salt thereof. 
     
     
         53 . The composition of  claim 3 , wherein the composition comprises about 1 mg/ml to about 100 mg/ml of the compound of Formula (I), or a pharmaceutically or nutraceutically acceptable salt thereof. 
     
     
         54 . The composition of  claim 53 , wherein the composition comprises about 1 mg/ml to about 50 mg/ml of the compound of Formula (I), or a pharmaceutically or nutraceutically acceptable salt thereof. 
     
     
         55 . The composition of  claim 53 , wherein the composition comprises about 5 mg/ml to about 15 mg/ml of the compound of Formula (I), or a pharmaceutically or nutraceutically acceptable salt thereof. 
     
     
         56 - 140 . (canceled)

Join the waitlist — get patent alerts

Track US2023371555A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.